HYPORT

Hypofractionated postoperative radiotherapy for prostate cancer: toxicity and quality of life (HYPORT) - HYPORT

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58171

Enrollment

180

Registered

2025-11-27

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Side effects and quality of life after postoperative hypofractionated radiotherapy for prostate cancer Observational period of 4 years post-treatment

Interventions

Hypofractionated radiotherapy

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: -    Indication for salvage or adjuvant postoperative radiotherapy after previous prostatectomy for T1-4 N0-1 M0 prostate cancer. -    HF dose-fractionation schedule with fraction size =2.5 Gray. -    Target volume is prostate bed +/- pelvic lymph node areas  

Exclusion criteria

Exclusion criteria: -    Previously RT in the pelvic region, for any reason. -    Diagnosed with another tumor in the past 6 months or known with tumor progression of other tumor. -    Unable or unwilling to fill out Dutch questionnaires online.  

Design outcomes

Primary

Measure	Time frame
Scores on the urinary and bowel module of the EPIC questionnaire	—

Secondary

Measure	Time frame
Establish levels of physician-reported toxicity scores according the CTCAE scoring system.	—

Countries

Netherlands

Contacts

Public ContactWD Wilma

Erasmus MC, Universitair Medisch Centrum Rotterdam

w.heemsbergen@erasmusmc.nl0650033202

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)